Recurrent Endometrial Cancer Clinical Trial
Official title:
A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients
Endometrial cancer ranks 11th in terms of incidence (7275 / year) and mortality (2025 deaths/ year). The 5-year overall survivals of patients at diagnosis with locally advanced and metastatic carcinomas are about 50% and 15% respectively. Beyond first line treatment with platinum-based chemotherapy, there is lack of effective drug in this disease, which explains the poor prognosis of patients. The prognosis of metastatic endometrial cancer patients is poor, and few drugs have been shown to be effective beyond first chemotherapy line. Endometrial carcinomas are characterized by frequent alterations of PI3K-AKT-mTor; IGF1R and of DNA repair pathways. Phosphatase and tensin homologue (PTEN)-phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTor) and DNA repair pathways interact, and inhibition of PI3K-AKT-mTor signaling pathway may alter DNA damage repair. Metronomic cyclophosphamide regimen may increase the anti-proliferative effects of olaparib because it is an alkylating agent, and it exerts anti-angiogenic effects, with a favorable toxicity profile. Metformin may increase the anti-proliferative effects of olaparib because it downregulates IGF1R and PI3K-AKT-mTor pathways, with no additive toxicity.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Active, not recruiting |
NCT02899793 -
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02788708 -
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03564340 -
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT01454479 -
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
|
Phase 1 | |
Terminated |
NCT03277482 -
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
|
Phase 1 | |
Terminated |
NCT04906382 -
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
|
Early Phase 1 | |
Withdrawn |
NCT02117817 -
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
Withdrawn |
NCT04197219 -
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05263492 -
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
|
Phase 2 |